

Warburg Pincus Completes Acquisition of DKSH's Healthcare Business in China

Shanghai, November 1, 2018 -- Warburg Pincus, a leading global private equity firm focused on growth investing, announced today that it has completed the acquisition of 100% stake of the China healthcare business from DKSH, the leading Market Expansion Services provider with a focus on Asia. The acquired business ("DKSH China Healthcare" or the "Company") will operate as an independent entity from November 1, 2018, and plans to launch a new brand in January 2019. This milestone transaction demonstrates the continued confidence in the healthcare sector in China by the firm.

DKSH China Healthcare focuses on the market expansion and distribution of pharmaceuticals, medical devices, and OTC / consumer health products in the country. The Company has established a nation-wide distribution network of unique scope and depth in the industry, supported by mature infrastructure and information system, as well as a highly-regarded professional team.

Headquartered in Zurich, Switzerland, DKSH Group is the leading Market Expansion Services provider with a long tradition of doing business in and with Asia. With over 150 years of history, its healthcare business in Asia spans across 13 Asian markets, including Cambodia, China, Hong Kong SAR, Indonesia, South Korea, Laos, Macao SAR, Malaysia, Myanmar, Singapore, Taiwan, Thailand and Vietnam. In July this year, Warburg Pincus reached an agreement with DKSH to acquire its healthcare business in China.

Mr. Min Fang, Managing Director of Warburg Pincus, commented, "We have a high regard for DKSH's reputation and professionalism in China's healthcare distribution industry. We look forward to partnering with the team to build the business into a leading healthcare services platform in China. China's healthcare industry presents tremendous opportunities for high-quality pharmaceutical and medical device products, and we are confident that the business will continue to introduce advanced healthcare products from global brands to Chinese patients and consumers."

"Warburg Pincus is committed to supporting the Company's management team and staff, and we will leverage our global resources, domestic network as well as capital strength, to accelerate the Company's growth" added Mr. Fang.

Mr. Stanley Jin, General Manager of DKSH's healthcare business, commented, "We have achieved significant competitive advantages in the healthcare market through our high level of professionalism, long-standing partnerships with leading multinational healthcare brands and companies and diversified business offerings. With additional capital strength and resources from Warburg Pincus, our business potential will be further unleashed. We look forward to a new chapter of accelerated growth as we embark on this exciting new journey."

In the future, Warburg Pincus has plans to upgrade supply chain capabilities, attract top-tier talents, and create synergies with Warburg Pincus global healthcare and logistics portfolio companies, and providing capital support to expand the scope of services for the Company's clients. In addition, the newly-acquired healthcare business in China has formed a strategic partnership with DKSH Group, drawing on strengths of both parties to ensure that the Company and DKSH Group will be collectively providing the best one-stop solutions for their clients in the region for years to come.

WARBURG PINCUS

Warburg Pincus LLC is a leading global private equity firm focused on growth investing. Founded in 1966, Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. The firm is global leader in healthcare investment with over US\$10 billion invested in more than 150 healthcare companies globally. In China, Warburg Pincus has a proven track record in investing and backing the growth of China healthcare brands since entering the Chinese market in 1994, such as Lepu Medical (SZSE: 300003), Wuxi AppTec (SHSE: 603259), China Biologic Products (NASDAQ: CBPO), Amcare Women's & Children's Hospital, and Jinxin Fertility.

Media Contact:

Mingxia Li

Warburg Pincus

+86 10 5923 2569

Mingxia.li@warburgpincus.com